Oxytocin Acetate*2mg Ara-290 OT2 RA10 BPC 10mg+GHK-Cu50mg+Tb500 10mg BBG70 China factory peptides
TDS 30 Inquiries
12656-61-0
Pharmaceutical Grade
99%
shenzhen
sc
2mg/10mg/70mg. 10 bottles per box
2027-12-31
tr
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionCertificates
-
TDS
Basic Info-
Product Name:
Cerebrolysin
Other Name:Cerebrolysin;FPE 1070
CAS No.:12656-61-0
EC Number:1592732-453-0
Categories:
Research-
Class:
Actin-sequestering protein / 43-amino-acid peptide
Status:Research compound — Not FDA approved (investigational: RGN-259 for dry eye / neurotrophic keratitis)
Mechanism:A naturally occurring 43-amino-acid peptide (Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser-OH) that binds G-actin (sequesters monomeric actin), preventing F-actin polymerization. Promotes cell migration, angiogenesis, wound healing, and anti-inflammatory responses via integrin-linked kinase (ILK) and HIF-1α/VEGF pathways. TB-500 is the synthetic fragment Ac-LKKTETQ (MW ~895) often sold under this CAS.
Activity note:Thymosin Beta-4 is an actin-binding protein, not a receptor agonist. Functional activity is measured by actin sequestration (Kd ~0.7–1 μM) and cell migration assays, not EC₅₀.
Source:Goldstein AL, et al. Vitam Horm. 2003;66:257–296. RegeneRx RGN-259 clinical program.DOI
Clinical Development:
References-
DrugBank:PubChem:UNII:Disclaimer:
Thymosin Beta-4 (TB-500) is NOT FDA-approved for human therapeutic use. RGN-259 (Tβ4 ophthalmic solution) is an investigational drug not yet approved. TB-500 sold on research-chemical marketplaces is a synthetic fragment and is not an approved medicine. This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
tr
-
Location:
B27 SHING LEE COMM BLDG 8WING KUT ST CENTRAL HONGKONG
-
Average lead Time:
1
-
Total Annual Revenue:
Less than $1 million
-
Total Employees:
5-10
-
Year of Establishment:
2026
-
-
Inquiry History30 Inquiries
Country Product Purchase Quantity Date Posted
India
High Quality cerebrolysin FPE 1070 Cerebrolysin powder 99% white powder 12656-61-0 Quanjinci
28 KG Sep 26, 2023
United States
CEREBROLYSIN
1 MT Mar 10, 2026
United Kingdom
Cerebrolysin (CBL60)
10 MG Jun 18, 2026
Brazil
Cerebrolysin
60 MG Apr 21, 2026
United States
Cerebrolysin
1 KG Mar 23, 2026
United States
Cerebrolysin
500 G Feb 9, 2026
South Africa
Cerebrolysin
1 KG Dec 29, 2025
United States
cerebrolysn
10 MG Dec 5, 2025
United States
Cerebrolysin
50 G Jul 17, 2025
Ireland
Cerebrolysin
1 Nov 4, 2024
United States
Cerebrolysin
10 G Jul 8, 2026
United States
Cerebrolysin
5 G Jun 29, 2026
Ireland
cerebrolysin
1 L Jun 26, 2026
United States
cerebrolysin
3 PCS May 13, 2026
South Africa
Cerebrolysin
1 KG Dec 29, 2025
United States
Cerebrolysin POWDER
1 G Dec 2, 2025
United Kingdom
Cerebrolysin Raw Powder
10 G Nov 3, 2025
South Korea
Cerebrolysin
1 G Jun 21, 2024
Uzbekistan
CEREBROLYSIN
1 KG Sep 22, 2023
United States
Cerebrolysin
60 MG Jun 26, 2026 Post an enquiry for this product